OnCore Login

Return to Trial Database

GU12-160

The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Cancer Research Network GU12-160

Status

Study Completed

Cancer Type(s)

Bladder

Study Contact

Publications

The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (Apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer
  • TK Choueiri, NM Hahn, SK Pal, AS Alva, R Dreicer, A Starodub, G Sonpavde, JH Hoffman-Censits, J Picus, AV Balar, EA Guancial, MM Regan, C Jacobs, PS Stewart, JE Rosenberg
Borealis-2: A randomized phase II study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial cancer (mUC)
  • TK Choueiri, NM Hahn, L Werner, MM Regan, JE Rosenberg

Trial Locations

All sites in which the trial GU12-160 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278